Answers are grounded in this paper and cite their sources.
Synthesizing pharmaceutical compounds demands exceptionally high structural precision, regio-selectivity, and absolute enantiomeric purity. Historically, reaching these target quality standards relied heavily on volatile organic solvents, heavy-metal catalysts, and multi-step protection strategies. Consequently, active pharmaceutical ingredient (API) production has generated disproportionately high Environmental Factors (E-factors, measured as kilograms of waste per kilogram of finalized drug product) compared to generic chemical sectors. Fundamental Paradigms: To resolve these sustainability hurdles, Anastas and Warner established foundational guidelines that prioritize waste elimination at the chemical design stage. Within active pharmaceutical synthesis, key priorities include:
No takes yet. Share an insight, caveat, or question.
Sahu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: